Aligos therapeutics on track to complete phase 2-enabling activities in 2023 for its clinically validated thr-ss drug candidate for nash, alg-055009

– final cohort of phase 1 study projected to be complete in h1 2023 –
ALGS Ratings Summary
ALGS Quant Ranking